SALIX PHARMACEUTICALS LTD 4
4 · SALIX PHARMACEUTICALS LTD · Filed Apr 17, 2013
Insider Transaction Report
Form 4
KEANE WILLIAM P
Director
Transactions
- Exercise/Conversion
Common Stock
2013-04-15$15.25/sh+30,000$457,398→ 63,202 total - Sale
Common Stock
2013-04-15$49.44/sh−30,000$1,483,200→ 33,202 total - Exercise/Conversion
Option to Buy Common Stock
2013-04-15−30,000→ 0 totalExercise: $15.25Exp: 2014-01-14→ Common Stock (30,000 underlying)
Holdings
- 15,000
Option to Buy Common Stock
Exercise: $17.63Exp: 2015-06-09→ Common Stock (15,000 underlying) - 22,500
Option to Buy Common Stock
Exercise: $18.87Exp: 2014-06-17→ Common Stock (22,500 underlying)
Footnotes (3)
- [F1]The exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2013.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.02 to $49.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]Options are 100% vested.